#United States #Spyre Therapeutics #Waltham #IBD #SPY002

Spyre Therapeutics to Host Conference Call

On June 17, 2025, Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company specializing in innovative antibody engineering, will report interim results from its Phase 1 clinical trials involving healthy volunteers for its groundbreaking SPY002 program. This program focuses on developing long-acting anti-TL1A antibodies aimed at effectively treating inflammatory bowel disease (IBD) and other immune-mediated disorders.

The Phase 1 trials are a critical step in evaluating the safety and efficacy of SPY002, designed to extend the half-life of this novel therapeutic agent. By optimizing the dosing and therapeutic combinations, Spyre Therapeutics aims to deliver a next-generation solution that could potentially revolutionize the management of IBD, a condition that affects millions of people worldwide.

The conference call will take place at 8 AM ET, where company leaders will discuss the clinical trial results and their implications for future development. Participants from the investment community and media are encouraged to join the call, which will also be available as a webcast. For those unable to attend, an archived version of the presentation will be made available on Spyre's Investor Relations website for a limited time, ensuring broad access to these critical updates.

In recent years, the demand for effective treatments for IBD has increased significantly as more individuals are diagnosed. Current therapies often come with considerable side effects or limitations that leave patients seeking alternative options. Spyre Therapeutics prides itself on advancing pharmaceutical science through cutting-edge research and development efforts, leveraging its expertise in antibody engineering.

The SPY002 program is part of a broader pipeline that includes extended half-life antibodies targeting key pathways involved in IBD, including α4β7 and IL-23. Each of these investigational treatments aims to address specific mechanisms of inflammation and immune response, enhancing the therapeutic toolbox available for healthcare providers.

About Spyre Therapeutics
Founded with a mission to innovate in the realm of immunology, Spyre Therapeutics has established itself as a leader in the field of antibody technology. The company’s team of experts is dedicated to discovering and developing new medications that address unmet medical needs. Their focus is not only on the creation of effective treatments but also ensuring that these innovations are accessible to patients.

The upcoming conference call represents an opportunity for stakeholders to gain insights into the progress of Spyre's clinical programs and the strategic direction of the company as it continues to push forward in the biotechnology landscape. For further details on the company and its initiatives, visit Spyre's website.

In conclusion, as Spyre Therapeutics gears up for this important announcement, the healthcare community will be keenly watching to see how the interim trial results for SPY002 may influence the future of treatment options for those suffering from IBD and related conditions.